Japanese Biotech Company Develops Revolutionary Tooth Regrowth Drug

In another viral tiktok video by @/AijaMayrock, the content creator shared the groundbreaking innovation of a Japanese biotech company that aims to regrow human teeth.

Toregem Biopharma, a Japanese biotechnology company, is at the forefront of advancement in dental care: a drug that has the potential to regenerate human teeth. This treatment, developed in collaboration with Kyoto University, could offer an alternative to traditional methods of addressing tooth loss and other dental issues

Targeting Tooth Loss Through Genetic Innovation

Toregem Biopharma, the biotechnology firm based in Japan, is making headlines with the development of a drug capable of regrowing human teeth. The treatment, which is currently undergoing clinical trials, works by targeting the USAG-1 protein. This gene naturally inhibits tooth regrowth in mammals, and by blocking its activity, the drug activates the body’s ability to regenerate teeth.

The drug works by stimulating the growth of new teeth, even in adults. It targets dormant “tooth buds” that usually disappear after childhood and are typically non-functional in adults. In a breakthrough, the drug activates these latent buds, counteracting the USAG-1 protein that suppresses tooth growth, effectively ‘reawakening’ them and encouraging the development of new teeth.

This discovery was first found in a laboratory mouse back in 2007, after which researchers saw encouraging results, such as the growth of new molars.

A Solution for Congenital and Acquired Tooth Loss

The primary focus of this treatment is individuals affected by tooth loss due to conditions like anodontia, a rare genetic disorder that causes missing teeth from birth. The video also states that 69% of adults lose at least one tooth due to tooth decay or disease.

It could also become a transformative solution for those who lose teeth to injury or decay. Early preclinical studies demonstrated the drug’s effectiveness in animal models, leading to the initiation of human trials in September 2024.

Human Trials and Future Prospects

The trials involve participants from various demographics, including children with congenital conditions and adults with tooth loss. If the trials prove successful, the treatment could be commercially available by 2030. This drug has the potential to replace traditional dental solutions like implants and dentures, offering a permanent and non-invasive alternative.

Interestingly, the company is targeting pediatric patients, particularly those suffering from anodontia. Toregem is planning to test the drug on children between the ages of two and seven, potentially offering these young patients a chance to grow natural, permanent teeth.

A Breakthrough in Restorative Medicine

Experts in the medical and dental fields view this innovation as a major advancement in genetic research and regenerative medicine. With millions affected by tooth loss globally, the drug’s success could open a new frontier in dental care, providing a natural and lasting solution to a widespread problem.

Recovery of congenital missing teeth in a mouse, via Toregem Pharma

Dr. Takahashi, a prominent medical professional from Kitano Hospital in Osaka, expressed , ‘We aim to support individuals affected by tooth loss or absence. While no permanent treatment has been available until now, we believe that the public’s expectations for tooth regeneration are growing.’

While side effects are still vague, Toregem Biopharma’s efforts exemplify how cutting-edge science can address everyday health challenges, making tooth regeneration a reality after decades of speculation and research.

Watch the video here:

@aijamayrock

I found the only drug in the world that can regrow teeth! 🦷 This is the ninth video in my series, Aging Around The World 🌍, where I explore how different countries and cultures tackle aging and longevity.

♬ original sound – Aija Mayrock

More of The Other Side: